Hyperbaric oxygen therapy prevents vascular derangement during zymosan-induced multiple-organ-failure syndrome.
D000704:Analysis of Variance; D000818:Animals; D001011:Aorta / Q000378:metabolism; D004730:Endothelium, Vascular / Q000502:physiology; D006931:Hyperbaric Oxygenation; D007150:Immunohistochemistry; D008297:Male; D008315:Malondialdehyde / Q000378:metabolism; D009102:Multiple Organ Failure / Q000503:physiopathology / Q000628:therapy*; D019001:Nitric Oxide Synthase / Q000378:metabolism; D052247:Nitric Oxide Synthase Type II; D011897:Random Allocation; D051381:Rats; D017207:Rats, Sprague-Dawley; D014443:Tyrosine / Q000031:analogs & derivatives* / Q000378:metabolism; D014652:Vascular Diseases / Q000517:prevention & control*; D014664:Vasodilation / Q000502:physiology; D015054:Zymosan
C002744:3-nitrotyrosine; D014443:Tyrosine; D008315:Malondialdehyde; D015054:Zymosan; D019001:Nitric Oxide Synthase; D052247:Nitric Oxide Synthase Type II; C496318:Nos2 protein, rat